Hematology

FDA approves pivekimab sunirine-pvzy for adults with BPDCN, offering a new CD123-directed therapy for this ultra-rare hematologic malignancy.

The FDA has granted traditional approval to nivolumab in cHL after autologous HSCT and brentuximab vedotin and after 3 or more lines of therapy.

Tazemetostat has been withdrawn from the market for all approved indications following safety data conveying secondary hematologic malignancy risk.

WVU Medicine has begun treating patients in the first clinical trial to explore the use of subcutaneous blinatumomab in patients with CD19-positive MPAL.

FDA fast-tracks trispecific IBI3003, reviews iberdomide combo, and expands Yescarta use.

The FDA approved a larger vial size of nelarabine for the treatment of pediatric and adult patients with T-ALL and T-LBL.

Expert advice for administering and monitoring liso-cel in patients with follicular lymphoma.

The microbiota-based therapy MaaT013 showed promising efficacy and manageable safety in those with acute GVHD with gastrointestinal involvement.

Subcutaneous daratumumab plus teclistamab improved survival outcomes in patients with R/R multiple myeloma vs standard daratumumab-based regimens.

Phase 2 data demonstrated similar pharmacokinetic profiles between subcutaneous azacitidine and an oral combination of azacitidine and cedazuridine.

Patients with relapsed/refractory large B-cell lymphoma treated with glofitamab or epcoritamab experienced early disease progression.

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk large B-cell lymphoma.

Phase 3 trial results demonstrated a significant benefit with the BTK inhibitor pirtobrutinib vs bendamustine plus rituximab in patients with untreated CLL/SLL.

Subcutaneous bispecific antibody cevostamab demonstrated early efficacy and safety in patients with relapsed or refractory multiple myeloma.

Pirtobrutinib demonstrated noninferior response rates to ibrutinib and showed a trend toward survival benefit in patients with CLL/SLL.

Patients with AML receiving azacitidine and venetoclax had significantly higher quality of life than those receiving intensive induction chemotherapy.

Blinatumomab/ponatinib increased efficacy, and response rates were improved in patients with Philadelphia-positive acute lymphoblastic leukemia.

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.

Older patients with newly diagnosed diffuse large B-cell lymphoma receiving epcoritamab plus R-mini-CHOP achieved deep responses with manageable safety.

Shifting to a higher and less frequent dose of axatilimab was tolerable and feasible in patients with chronic GVHD.

KRd demonstrated higher PFS, deeper response, and greater MRD negativity compared with VRd in newly diagnosed multiple myeloma.

The combination of odronextamab with CHOP chemotherapy showed early efficacy in patients with untreated diffuse large B-cell lymphoma.

Nearly one-third of families of children with acute lymphoblastic leukemia developed “catastrophic” financial toxicity during the patient’s treatment.

Higher LDH levels were linked with poorer survival outcomes in patients with relapsed and refractory multiple myeloma who received elranatamab.

Fixed-duration venetoclax combined with obinutuzumab or ibrutinib produced noninferior PFS compared with continuous ibrutinib monotherapy.